Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China
Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China
复制标题
不同 EBV 抗原抗体的多参数检测预测中国高危人群鼻咽癌风险
DOI：
10.1158/1940-6207.capr-17-0035
复制
发表时间：
2017-09-01
影响因子：
3.3
通讯作者：
Liu, Wanli
中科院分区：
文献类型：
--
作者：
Chen, Hao;Chen, Shulin;Liu, Wanli
本研究旨在利用EB病毒（Epstein-Barr virus，EBV）抗原的多种抗体联合检测，建立鼻咽癌筛查和诊断模型。300例鼻咽癌患者和494例对照，包括294例健康受试者（HC），99例非鼻咽癌癌症患者（NNPC）和101例良性鼻咽病变（BNL）患者，与EUROLINE Anti-EBV Profile 2孵育，并使用条带强度建立风险预测模型。基于VCAgp 125伊加、EBNA-1 IgA、EA-D伊加、EBNA-1 IgG、EAD IgG和VCAp 19 IgG的鼻咽癌风险概率分析显示出最佳性能。以26.1%为界值进行ROC分析，鼻咽癌和所有对照组的AUC值和敏感性/特异性分别为0.951和90.7%/86.2%。鼻咽癌组、非鼻咽癌组和BNL组的AUC值和敏感性/特异性分别为0.957和90.7%/88.1%。EUROLINE Anti-EBV Profile 2检测对鼻咽癌和早期鼻咽癌的诊断特异性和敏感性均高于免疫酶联法和实时荧光PCR（EBVDNA）单抗体检测。在VCA-IgA阴性组中，82.6%的鼻咽癌患者显示鼻咽癌的高概率，阴性预测值为97.1%。在VCA-IgA阳性组中，73.3%的健康受试者表现出低概率。本组阳性预测值达98.2%。结论：EUROLINE Anti-EBV Profile 2测定鼻咽癌风险概率值可作为鼻咽癌筛查的一种有效工具。(C)2017年AACR。
In this study, we aimed to use the combined detection of multiple antibodies against Epstein-Barr virus (EBV) antigens to develop a model for screening and diagnosis of nasopharyngeal carcinoma (NPC). Samples of 300 nasopharyngeal carcinoma patients and 494 controls, including 294 healthy subjects (HC), 99 non-nasopharyngeal carcinoma cancer patients (NNPC), and 101 patients with benign nasopharyngeal lesions (BNL), were incubated with the EUROLINE Anti-EBV Profile 2, and band intensities were used to establish a risk prediction model. The nasopharyngeal carcinoma risk probability analysis based on the panel of VCAgp125 IgA, EBNA-1 IgA, EA-D IgA, EBNA-1 IgG, EAD IgG, and VCAp19 IgG displayed the best performance. When using 26.1% as the cutoff point in ROC analysis, the AUC value and sensitivity/specificity were 0.951 and 90.7%/86.2%, respectively, in nasopharyngeal carcinoma and all controls. In nasopharyngeal carcinoma and controls without the non-nasopharyngeal carcinoma and BNL groups, the AUC value and sensitivity/specificity were 0.957 and 90.7%/88.1%, respectively. The diagnostic specificity and sensitivity of the EUROLINE Anti-EBV Profile 2 assay for both nasopharyngeal carcinoma and early-stage nasopharyngeal carcinoma were higher than that of mono-antibody detection by immune-enzymatic assay and real-time PCR(EBVDNA). In the VCA-IgA-negative group, 82.6% of nasopharyngeal carcinoma patients showed high probability for nasopharyngeal carcinoma, and the negative predictive value was 97.1%. In the VCA-IgA-positive group, 73.3% of healthy subjects showed low probability. The positive predictive value reached 98.2% in this group. The nasopharyngeal carcinoma risk probability value determined by the EUROLINE Anti-EBV Profile 2 might be a suitable tool for nasopharyngeal carcinoma screening. (C) 2017 AACR.